PICO Portalanswers from OpenAlex
Centre de Recherches en Cancérologie de Toulouse
InstitutionResearch output, impact & collaborations
Centre de Recherches en Cancérologie de Toulouse is a institution indexed in PICO Portal from OpenAlex.
What is known about Centre de Recherches en Cancérologie de Toulouse?
PICO Portalrecord summary
Centre de Recherches en Cancérologie de Toulouse is a research organisation in Toulouse, FR. OpenAlex records 4,150 works and 584,317 citations for it. 1,053 researchers list it as their most recent affiliation.
How many works does Centre de Recherches en Cancérologie de Toulouse have?
PICO Portalindexed works
Centre de Recherches en Cancérologie de Toulouse has 4,150 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Centre de Recherches en Cancérologie de Toulouse have?
PICO Portalcitation count
Centre de Recherches en Cancérologie de Toulouse has 584,317 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at Centre de Recherches en Cancérologie de Toulouse?
PICO Portalresearcher count
Centre de Recherches en Cancérologie de Toulouse has 1,053 researchers in the PICO Portal index.
What is the average h-index at Centre de Recherches en Cancérologie de Toulouse?
PICO Portalavg h-index
Centre de Recherches en Cancérologie de Toulouse has an average h-index of 65 in OpenAlex.
What is the ROR of Centre de Recherches en Cancérologie de Toulouse?
PICO Portalror
The ROR for Centre de Recherches en Cancérologie de Toulouse is on the source record.
What is the OpenAlex record for Centre de Recherches en Cancérologie de Toulouse?
PICO Portalopenalex
The OpenAlex for Centre de Recherches en Cancérologie de Toulouse is on the source record.
What is the Wikidata of Centre de Recherches en Cancérologie de Toulouse?
PICO Portalwikidata
The Wikidata for Centre de Recherches en Cancérologie de Toulouse is on the source record.
Who are the most-cited researchers behind Centre de Recherches en Cancérologie de Toulouse?
PICO Portaltop researchers by citations
What are the most-cited papers on Centre de Recherches en Cancérologie de Toulouse?
PICO Portalmost cited works
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung‐Ju Ahn, Ainara Soria, Jean‐Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan D. Cheng, Ramona F. Swaby, Kevin J. Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Myung‐Ju Ahn, Mario Airoldi, Eduardas Aleknavičius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra E.W. Cohen, Tibor Csőszi, Jan Paul de Boer, Jean‐Pierre Delord, Andreas Dietz, José Dinis, Charlotte Dupuis, Laurence Digue, József Erfán, Yolanda Escobar Alvarez, Mererid Evans, Mary J. Fidler, Martin Förster, Signe Friesland, Apar Kishor Ganti, Lionnel Geoffrois, Clíona Grant, Viktor Gruenwald, Kevin J. Harrington, Thomas K. Hoffmann, Geza Horvai, Arturas Inčiūra, Raymond Woo-Jun Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juárez Ramiro, Bogusława Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung‐Bae Kim, Judit Kocsis, Nuria Kotecki, Mark Kozloff, J. Lambea, László Landherr, Yuri Lantsukhay, Sergey Lazarev, Lip Way Lee, Christophe Le Tourneau, Lisa Licitra, Igor Lifirenko, Nicolas Mach, Danko Martincic, О. В. Маторин, Margaret McGrath, Jean‐Pascal Machiels, Ranee Mehra, Krzysztof Misiukiewicz, John C. Morris, Ф. Ф. Муфазалов, Jiaxin Niu, Devraj Srinivasan, Pedro Pérez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina P. Rodriguez, Frédéric Rolland, Antonio Russo, Ágnes Ruzsa, Frederico Sanches, Sangwon Shin, Mikhail Shtiveland
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, Fabrice André, Jean‐Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schüler, Ulka N. Vaishampayan, Howard A. Burris, Guangming Tian, Mario Campone, Zev A. Wainberg, Wan‐Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, François Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin, Jean‐Charles Soria, Anastasios Stathis, Jean‐Pierre Delord, Solange Peters, Ahmad Awada, Philippe Aftimos, Mohamed Békradda, Keyvan Rezaï, Zhen Zeng, Azher Hussain, Susan Perez, Lillian L. Siu, Christophe Massard
How much of the research on Centre de Recherches en Cancérologie de Toulouse is open access?
PICO Portalopen access share
50%OPEN ACCESS